Rifampicin
- Generic Name
- Rifampicin
- Brand Names
- Isonarif, Rifadin, Rifamate, Rifater, Rofact
- Drug Type
- Small Molecule
- Chemical Formula
- C43H58N4O12
- CAS Number
- 13292-46-1
- Unique Ingredient Identifier
- VJT6J7R4TR
- Background
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericid...
- Indication
Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.
- Associated Conditions
- Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis
- Associated Therapies
- Antibacterial therapy
TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.
- Conditions
- Interventions
- First Posted Date
- 2008-08-26
- Last Posted Date
- 2013-04-18
- Lead Sponsor
- Tibotec Pharmaceuticals, Ireland
- Target Recruit Count
- 21
- Registration Number
- NCT00741169
A Pilot Study of Inflammatory Markers in Alzheimer's Disease
- First Posted Date
- 2008-07-15
- Last Posted Date
- 2009-02-04
- Lead Sponsor
- McMaster University
- Target Recruit Count
- 21
- Registration Number
- NCT00715858
- Locations
- 🇨🇦
St.Peter's Hospital, Hamilton, Ontario, Canada
Randomized Clinical Trial to Compare a Regimen of Trimethoprim-sulfamethoxazole Plus Rifampicin With a Regimen of Linezolid in the Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection
- Conditions
- Interventions
- First Posted Date
- 2008-07-09
- Last Posted Date
- 2014-08-05
- Lead Sponsor
- University Hospital, Geneva
- Target Recruit Count
- 150
- Registration Number
- NCT00711854
- Locations
- 🇨🇭
Geneva University Hospitals, Geneva, Switzerland
TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment
- First Posted Date
- 2008-06-10
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 865
- Registration Number
- NCT00694629
- Locations
- 🇺🇸
Washington DC Veterans Administration Medical Center, Washington DC, District of Columbia, United States
🇪🇸Agencia de Salut Publica, Barcelona, Spain
🇺🇸University of North Texas Health Science Center, Fort Worth, Texas, United States
Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions
- Conditions
- Interventions
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 29
- Registration Number
- NCT00621309
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸UW General Clinical Research Center, Seattle, Washington, United States
A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
- First Posted Date
- 2008-01-03
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 596
- Registration Number
- NCT00585195
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸The James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
Controlled Trial: 5-day Course of Rifampin Versus Doxycycline for the Treatment of Mild to Moderate Scrub Typhus
- First Posted Date
- 2007-12-06
- Last Posted Date
- 2019-02-08
- Lead Sponsor
- Dong-Min Kim
- Target Recruit Count
- 476
- Registration Number
- NCT00568711
- Locations
- 🇰🇷
Chosun University Hospital, Gwangju, Jeonnam, Korea, Republic of
A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer
- Conditions
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00534807
- Locations
- 🇺🇸
Local Institution, Detroit, Michigan, United States
Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid
- Conditions
- Interventions
- First Posted Date
- 2007-02-23
- Last Posted Date
- 2018-03-19
- Lead Sponsor
- Hamilton Health Sciences Corporation
- Target Recruit Count
- 100
- Registration Number
- NCT00439166
- Locations
- 🇨🇦
St.Peter's Hospital, Hamilton, Ontario, Canada
Effect of a Potent Inducer Rifampicin on the Pharmacokinetics of Deferasirox in Healthy Volunteers
- Conditions
- First Posted Date
- 2007-01-08
- Last Posted Date
- 2009-11-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 22
- Registration Number
- NCT00419172
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.